N/A
N=54
Natriuretic Peptide Concentrations of B-type (BNP) During Anesthesia in Patients Previously Sensitized to Anthracyclines
Breast Cancer
Bottom Line
View on ClinicalTrials.gov: NCT01754597 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Pre-operative Concentration of NT-proBNP — 38.9; 32.2 pg/ml — p=0.714
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Dosage of B-type natriuretic peptide (NT-proBNP) (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Institut Bergonié
- Primary completion
- Dec 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pre-operative Concentration of NT-proBNP |
38.9; 32.2 | 0.714 |
| PRIMARY Concentration of NT-proBNP at the End of Intervention |
42.2; 34.6 | 0.492 |
| PRIMARY Post-operative Concentration of NT-proBNP |
107.6; 75.9 | 0.183 |
Summary
The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical and echocardiographic monitoring. In the case of treatment for breast cancer, surgery requiring general anesthesia may follow chemotherapy. Although a possible interaction between general anesthetics and anthracyclines on systolic function is only rarely mentioned, some cases of heart failure and / or conduction disturbances peranesthésique were observed in patients treated or previously treated with anthracyclines. The determination of concentration of BNP is a diagnostic tool used in the detection of heart failure and acute coronary syndromes. The question of a possible synergism between cardiotoxic anthracyclines and anesthetic agents arises. Given its minimally invasive nature and its diagnostic value, the BNP assay might thus allow to highlight a possible subclinical deficiency. To our knowledge, there is very little data regarding a possible synergism between cardiotoxic anthracyclines and anesthetic agents.
Eligibility Criteria
Inclusion Criteria
- Women over 18 years with effective contraceptive method (if applicable)
- NT-proBNP <125 pg / ml
- ASA 1 or 2,
- Breast cancer histologically proven
- Mastectomy or lumpectomy
- Neoadjuvant chemotherapy with anthracyclines in 6 months or received no chemotherapy with anthracyclines,
- Patients who received the briefing and signed the informed consent
- Patients affiliated to a social security system.
Exclusion Criteria
- Patients for whom the maintenance of general anesthesia does not use halogenated.
- Renal impairment: Creatinine clearance <60 ml / min,
- Patients who for reasons psychological, social, family or geographical could not be treated or monitored regularly according to the criteria of the study, patients deprived of liberty or under guardianship.
- Presence of a cardiopathy
- Pregnant Women
Data sourced from ClinicalTrials.gov (NCT01754597). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.